Catalent Signs RL21 Anti-Cancer Development Deal with Pure MHC - - BioPharm International

ADVERTISEMENT

Catalent Signs RL21 Anti-Cancer Development Deal with Pure MHC


Catalent announced that it has signed a product development agreement with immunology company Pure MHC (major histocompatibility complex), which specializes in MHC-based diagnostics and therapeutics.

Under the terms of the agreement, Catalent will develop a humanized version of Pure MHC’s proprietary RL21A antibody and engineer a cell line to express the antibody using Catalent’s GPEx technology. Catalent will subsequently produce purified monoclonal antibodies to support Pure MHC’s preclinical development in preparation for clinical trials with humanized RL21A for the treatment of cancer. GPEx technology is used to generate mammalian cells with high yields and stability, helping to speed drugs to clinic.


Pure MHC has developed a suite of MHC/ligand targets that recognize cancerous cells in addition to producing monoclonal antibodies for these distinct MHC/ligand cancer targets. Antibodies such as RL21A distinguish primary cancers from healthy tissue and, in animal models, have been shown to arrest tumor development.


Source: Catalent

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Baxter Issues Recall Due to Particulate Matter
July 11, 2014
Hospira Issues Recall Due to Mold Contamination
July 11, 2014
EMA Recommends 39 Drugs in First Half of 2014
July 10, 2014
Biotech Industry Forms International Council
July 10, 2014
FDA Publishes Guidance on ANDA Submissions
July 10, 2014
Author Guidelines

Click here